The Baseline Panel — Page 2

Other inherited cancer genes rival BRCA mutations in clinical importance and screening impact.

Genetic variants of uncertain significance affect one in three patients, often for years.

Genetic risk scores work best for patients standard calculators can't confidently categorize.

Exome sequencing offers better odds and lower costs for healthy adults without genetic red flags.

Health systems are shifting genetic drug testing from reactive fix to preventive habit.

AI excels at imaging but risks silent errors when clinicians trust its confidence too much.

Learn which abnormal biomarkers deserve a repeat test before you act.

Membership medicine programs price risk by managing small, concentrated pools of patients.

Whole-genome sequencing shifts prevention from detection to genuine risk identification.